Scotts Miracle-Gro SMG Cost of sales—impairment, restructuring and other
Cost of sales—impairment, restructuring and other at other companies
Other financials
Where this comes from
Reported directly by Scotts Miracle-Gro in its filing.
Tagged under the XBRL concept smg:CostOfSalesImpairmentRestructuringAndOtherCharges.
The official record: Scotts Miracle-Gro’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Scotts Miracle-Gro's cost of sales—impairment, restructuring and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Scotts Miracle-Gro's cost of sales—impairment, restructuring and other?
- Scotts Miracle-Gro (SMG) reported cost of sales—impairment, restructuring and other of $0 in Q1 2026.
- How has Scotts Miracle-Gro's cost of sales—impairment, restructuring and other changed year-over-year?
- Scotts Miracle-Gro's cost of sales—impairment, restructuring and other decreased by 100.0% year-over-year, from $5.3M to $0.
- What is the long-term trend for Scotts Miracle-Gro's cost of sales—impairment, restructuring and other?
- Over 4 years (2021 to 2025), Scotts Miracle-Gro's cost of sales—impairment, restructuring and other has grown at a -12.3% compound annual growth rate (CAGR), from $24.7M to $14.6M.
- What does cost of sales—impairment, restructuring and other mean?
- This metric represents non-recurring or extraordinary costs directly associated with the production and supply chain process, such as asset write-downs or facility optimization expenses. It captures the impact of operational restructuring on the cost of goods sold, distinguishing these transitory charges from standard manufacturing expenses. Investors use this to assess the underlying efficiency of core production activities by isolating one-time operational disruptions.